Humanized immune system animal models and their recent applications

Abstract

Human or humanized immune system (HIS) animal models have emerged as indispensable tools for studying human biology and disease in vivo. By engrafting human hematopoietic and hematopoietic stem cells (HSC) into immunodeficient hosts, these models have enabled the development of a functional HIS, allowing the study of immune responses, disease mechanisms, and therapeutic interventions in a physiologically relevant setting. HIS models have broad applications across cancer research, infectious disease, regenerative medicine, and immunotherapy development. This review provides a comprehensive overview of the current landscape of HIS model generation, including HSC-based approaches, host strain selection, and recent advances involving genetically engineered mouse models expressing human cytokines and human leukocyte antigen molecules. We evaluated the strengths and limitations of these models, including issues with incomplete immune reconstitution and species-specific incompatibilities. We also discuss their increasing role in preclinical drug development and explore emerging innovations such as multitissue humanization and genome-editing strategies. As HIS models continue to evolve, they provide strong opportunities to bridge basic research and clinical translation.

Keywords

animal science / humanized mice / immunotherapy / patient-derived xenografts / vaccines

References

[1] Walsh NC, Kenney LL, Jangalwe S, et al. Humanized mouse models of clinical disease. Annu Rev Pathol Mech Dis. 2017; 12: 187-215.

[2] Allen TM, Brehm MA, Bridges S, et al. Humanized immune system mouse models: progress, challenges and opportunities. Nat Immunol. 2019; 20(7): 770-774.

[3] Kersten K, de Visser KE, van Miltenburg MH, Jonkers J. Genetically engineered mouse models in oncology research and cancer medicine. EMBO Mol Med. 2017; 9(2): 137-153.

[4] Skelton JK, Ortega-Prieto AM, Dorner M. A Hitchhiker’s guide to humanized mice: new pathways to studying viral infections. Immunology. 2018; 154(1): 50-61.

[5] Alves da Costa T, Lang J, Torres RM, Pelanda R. The development of human immune system mice and their use to study tolerance and autoimmunity. J Transl Autoimmun. 2019; 2:100021.

[6] Pearson T, Greiner DL, Shultz LD. Creation of “humanized” mice to study human immunity. Curr Protoc Immunol. 2008; 81(SUPPL. 81): 15.21.1-15.21.21.

[7] De La Rochere P, Guil-Luna S, Decaudin D, Azar G, Sidhu SS, Piaggio E. Humanized mice for the study of immuno-oncology. Trends Immunol. 2018; 39(9): 748-763.

[8] Drake AC, Chen Q, Chen J. Engineering humanized mice for improved hematopoietic reconstitution. Cell Mol Immunol. 2012; 9(3): 215-224.

[9] Bueno C, Montes R, De La Cueva T, Gutierrez-Arnda I, Menendez P. Intra-bone marrow transplantation of human CD34⁺ cells into NOD/LtSz-scid IL-2rγnull mice permits multilineage engraftment without previous irradiation. Cytotherapy. 2010; 12(1): 45-49.

[10] Adigbli G, Ménoret S, Cross AR, Hester J, Issa F, Anegon I. Humanization of immunodeficient animals for the modeling of transplantation, graft versus host disease, and regenerative medicine. Transplantation. 2020; 104(11): 2290-2306.

[11] Ito R, Katano I, Kawai K, et al. A novel xenogeneic graft-versus-host disease model for investigating the pathological role of human CD4⁺ or CD8⁺ T cells using immunodeficient NOG mice. Am J Transplant. 2017; 17(5): 1216-1228.

[12] Ito M, Hiramatsu H, Kobayashi K, et al. NOD/SCID/γcnull mouse: an excellent recipient mouse model for engraftment of human cells. Blood. 2002; 100(9): 3175-3182.

[13] Abarrategi A, Mian SA, Passaro D, Rouault-Pierre K, Grey W, Bonnet D. Modeling the human bone marrow niche in mice: from host bone marrow engraftment to bioengineering approaches. J Exp Med. 2018; 215(3): 729-743.

[14] Verma B, Wesa A. Establishment of humanized mice from peripheral blood mononuclear cells or cord blood CD34⁺ hematopoietic stem cells for immune-oncology studies evaluating new therapeutic agents. Curr Protoc Pharmacol. 2020; 89(1):e77.

[15] Audigé A, Rochat MA, Li D, et al. Long-term leukocyte reconstitution in NSG mice transplanted with human cord blood hematopoietic stem and progenitor cells. BMC Immunol. 2017; 18(1):28.

[16] Lepus CM, Gibson TF, Gerber SA, et al. Comparison of human fetal liver, umbilical cord blood, and adult blood hematopoietic stem cell engraftment in NOD-scid/γc−/−, Balb/c-Rag1−/−γc−/−, and C.B-17-scid/bg immunodeficient mice. Hum Immunol. 2009; 70(10): 790-802.

[17] Hess NJ, Lindner PN, Vazquez J, et al. Different human immune lineage compositions are generated in non-conditioned NBSGW mice depending on HSPC source. Front Immunol. 2020; 11:573406.

[18] Maurice Morillon Y, Sabzevari A, Schlom J, Greiner JW. The development of next-generation PBMC humanized mice for preclinical investigation of cancer immunotherapeutic agents. Anticancer Res. 2020; 40(10): 5329-5341.

[19] Holguin L, Echavarria L, Burnett JC. Novel humanized peripheral blood mononuclear cell mouse model with delayed onset of graft-versus-host disease for preclinical HIV research. J Virol. 2022; 96(3):e0139421.

[20] Brehm MA, Kenney LL, Wiles MV, et al. Lack of acute xenogeneic graft-versus-host disease, but retention of T-cell function following engraftment of human peripheral blood mononuclear cells in NSG mice deficient in MHC class I and II expression. FASEB J. 2019; 33(3): 3137-3151.

[21] Shultz LD, Lyons BL, Burzenski LM, et al. Human lymphoid and myeloid cell development in NOD/LtSz- scid IL2R γ null mice engrafted with mobilized human hemopoietic stem cells. J Immunol. 2005; 174(10): 6477-6489.

[22] Chandra S, Cristofori P, Fonck C, O’Neill CA. Ex vivo gene therapy: graft-versus-host disease (GVHD) in NSG^TM (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice transplanted with CD34⁺ human hematopoietic stem cells. Toxicol Pathol. 2019; 47(5): 656-660.

[23] Barve A, Casson L, Krem M, Wunderlich M, Mulloy JC, Beverly LJ. Comparative utility of NRG and NRGS mice for the study of normal hematopoiesis, leukemogenesis, and therapeutic response. Exp Hematol. 2018; 67: 18-31.

[24] Pearson T, Shultz LD, Miller D, et al. Non-obese diabetic-recombination activating gene-1 (NOD-Rag1 null) interleukin (IL)-2 receptor common gamma chain (IL2rγnull) null mice: a radioresistant model for human lymphohaematopoietic engraftment. Clin Exp Immunol. 2008; 154(2): 270-284.

[25] Smutova V, Pará C, Foret MK, et al. Non-clinical cell therapy development using the NCG mouse model as a test system. Int J Toxicol. 2023; 42(3): 232-253.

[26] Chen SS, Wang H, Fan J, et al. NCG-M humanized mice—an excellent model for human immune reconstitution of myeloid lineages. J Immunol. 2023; 210(Supplement_1):169.06.

[27] Ito M, Kobayashi K, Nakahata T. NOD/Shi-scid IL2rγnull (NOG) mice more appropriate for humanized mouse models. Curr Top Microbiol Immunol. 2008; 324: 53-76.

[28] Willis E, Verrelle J, Banerjee E, et al. Humanization with CD34-positive hematopoietic stem cells in NOG-EXL mice results in improved long-term survival and less severe myeloid cell hyperactivation phenotype relative to NSG-SGM3 mice. Vet Pathol. 2024; 61(4): 664-674.

[29] Kostlan RJ, Phoenix JT, Budreika A, et al. Clinically relevant humanized mouse models of metastatic prostate cancer facilitate therapeutic evaluation. Mol Cancer Res. 2024; 22(9): 826-839.

[30] Shultz LD, Brehm MA, Victor Garcia-Martinez J, Greiner DL. Humanized mice for immune system investigation: Progress, promise and challenges. Nat Rev Immunol. 2012; 12(11): 786-798.

[31] Coughlan AM, Harmon C, Whelan S, et al. Myeloid engraftment in humanized mice: impact of granulocyte-colony stimulating factor treatment and transgenic mouse strain. Stem Cells Dev. 2016; 25(7): 530-541.

[32] Jangalwe S, Shultz LD, Mathew A, Brehm MA. Improved B cell development in humanized NOD-scid IL2Rγnull mice transgenically expressing human stem cell factor, granulocyte-macrophage colony-stimulating factor and interleukin-3. Immunity Inflamm Dis. 2016; 4(4): 427-440.

[33] Kim JT, Bresson-Tan G, Zack JA. Current advances in humanized mouse models for studying NK cells and HIV infection. Microorganisms. 2023; 11(8):1984.

[34] Tarrant JC, Binder ZA, Bugatti M, et al. Pathology of macrophage activation syndrome in humanized NSGS mice. Res Vet Sci. 2021; 134: 137-146.

[35] Janke LJ, Imai DM, Tillman H, et al. Development of mast cell and eosinophil hyperplasia and HLH/MAS-like disease in NSG-SGM3 mice receiving human CD34⁺ hematopoietic stem cells or patient-derived leukemia xenografts. Vet Pathol. 2021; 58(1): 181-204.

[36] Perdomo-Celis F, Medina-Moreno S, Davis H, Bryant J, Zapata JC. HIV replication in humanized IL-3/GM-CSF-transgenic NOG mice. Pathogens. 2019; 8(1):33.

[37] Ito R, Nagai D, Igo N, et al. A novel in vivo model for predicting myelotoxicity of chemotherapeutic agents using IL-3/GM-CSF transgenic humanized mice. Toxicol Lett. 2017; 281: 152-157.

[38] Maser IP, Hoves S, Bayer C, et al. The tumor milieu promotes functional human tumor-resident plasmacytoid dendritic cells in humanized mouse models. Front Immunol. 2020; 11:2082.

[39] Katano I, Nishime C, Ito R, et al. Long-term maintenance of peripheral blood derived human NK cells in a novel human IL-15- transgenic NOG mouse. Sci Rep. 2017; 7(1):17230.

[40] Aryee KE, Burzenski LM, Yao LC, et al. Enhanced development of functional human NK cells in NOD-scid-IL2rgnull mice expressing human IL15. FASEB J. 2022; 36(9):e22476.

[41] Hanazawa A, Ito R, Katano I, et al. Generation of human immunosuppressive myeloid cell populations in human interleukin-6 transgenic NOG mice. Front Immunol. 2018; 9(FEB):152.

[42] Hasanali ZS, Garfall AL, Burzenski L, et al. Human IL-6 fosters long-term engraftment of patient-derived disease-driving myeloma cells in immunodeficient mice. JCI Insight. 2024; 9(10):e177300.

[43] Katano I, Takahashi T, Ito R, et al. Predominant development of mature and functional human NK cells in a novel human IL-2–producing transgenic NOG mouse. J Immunol. 2015; 194(7): 3513-3525.

[44] Jespersen H, Lindberg MF, Donia M, et al. Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model. Nat Commun. 2017; 8(1):707.

[45] Yaguchi T, Kobayashi A, Inozume T, et al. Human PBMC-transferred murine MHC class I/II-deficient NOG mice enable long-term evaluation of human immune responses. Cell Mol Immunol. 2018; 15(11): 953-962.

[46] Verma B, Ritchie M, Mancini M. Development and applications of patient-derived xenograft models in humanized mice for oncology and immune-oncology drug discovery. Curr Protoc Pharmacol. 2017; 2017: 14.41.1-14.41.12.

[47] Fiorini C, Abdulhay NJ, McFarland SK, et al. Developmentally-faithful and effective human erythropoiesis in immunodeficient and kit mutant mice. Am J Hematol. 2017; 92(9): E513-E519.

[48] Leonard A, Yapundich M, Nassehi T, et al. Low-dose busulfan reduces human CD34⁺ cell doses required for engraftment in c-kit mutant immunodeficient mice. Mol Ther Methods Clin Dev. 2019; 15: 430-437.

[49] Samal J, Kelly S, Na-Shatal A, et al. Human immunodeficiency virus infection induces lymphoid fibrosis in the BM-liver-thymus-spleen humanized mouse model. JCI Insight. 2018; 3(18):e120430.

[50] Smith DJ, Lin LJ, Moon H, et al. Propagating humanized BLT mice for the study of human immunology and immunotherapy. Stem Cells Dev. 2016; 25(24): 1863-1873.

[51] Marsden MD, Kovochich M, Suree N, et al. HIV latency in the humanized BLT mouse. J Virol. 2012; 86(1): 339-347.

[52] Brainard DM, Seung E, Frahm N, et al. Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. J Virol. 2009; 83(14): 7305-7321.

[53] Weaver JL, Zadrozny LM, Gabrielson K, Semple KM, Shea KI, Howard KE. BLT-immune humanized mice as a model for nivolumab-induced immune-mediated adverse events: comparison of the NOG and Nog-Exl strains. Toxicol Sci. 2019; 169(1): 194-208.

[54] Agarwal Y, Beatty C, Ho S, et al. Development of humanized mouse and rat models with full-thickness human skin and autologous immune cells. Sci Rep. 2020; 10(1):14598.

[55] Ménoret S, Ouisse LH, Tesson L, et al. In vivo analysis of human immune responses in immunodeficient rats. Transplantation. 2020; 104(4): 715-723.

[56] Jung CJ, Menoret S, Brusselle L, et al. Comparative analysis of piggyBac, CRISPR/Cas9 and TALEN mediated BAC transgenesis in the zygote for the generation of humanized SIRPA rats. Sci Rep. 2016; 6:31455.

[57] Liu Y, Wu W, Cai C, Zhang H, Shen H, Han Y. Patient-derived xenograft models in cancer therapy: technologies and applications. Signal Transduct Target Ther. 2023; 8(1):160.

[58] Morton JJ, Bird G, Refaeli Y, Jimeno A. Humanized mouse xenograft models: narrowing the tumor-microenvironment gap. Cancer Res. 2016; 76(21): 6153-6158.

[59] Rongvaux A, Willinger T, Martinek J, et al. Development and function of human innate immune cells in a humanized mouse model. Nat Biotechnol. 2014; 32(4): 364-372.

[60] Rosewell Shaw A, Porter CE, Yip T, et al. Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors. Commun Biol. 2021; 4(1):368.

[61] Lin S, Huang G, Cheng L, et al. Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy. MAbs. 2018; 10(8): 1301-1311.

[62] Meraz IM, Majidi M, Meng F, et al. An improved patient-derived xenograft humanized mouse model for evaluation of lung cancer immune responses. Cancer Immunol Res. 2019; 7(8): 1267-1279.

[63] Capasso A, Lang J, Pitts TM, et al. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. J Immunother Cancer. 2019; 7(1):37.

[64] Takei J, Furudate K, Nagaoka-Kamata Y, et al. Exploring the immune environment of glioblastoma through single-cell RNA sequencing in humanized mouse models. bioRxiv [Preprint]. 2025.

[65] Choi B, Lee JS, Kim SJ, Hong D, Park JB, Lee KY. Anti-tumor effects of anti-PD-1 antibody, pembrolizumab, in humanized NSG PDX mice xenografted with dedifferentiated liposarcoma. Cancer Lett. 2020; 478: 56-69.

[66] Liu WN, Fong SY, Tan WWS, et al. Establishment and characterization of humanized mouse NPC-PDX model for testing immunotherapy. Cancers (Basel). 2020; 12(4):1025.

[67] Zhao Y, Shuen TWH, Toh TB, et al. Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy. Gut. 2018; 67(10): 1845-1854.

[68] Choi Y, Lee S, Kim K, Kim SH, Chung YJ, Lee C. Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice. Exp Mol Med. 2018; 50(8): 1-9.

[69] Jin CH, Xia J, Rafiq S, et al. Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia. EBioMedicine. 2019; 39: 173-181.

[70] Mhaidly R, Verhoeyen E. Humanized mice are precious tools for preclinical evaluation of car t and car nk cell therapies. Cancers (Basel). 2020; 12(7):1915.

[71] Shultz LD, Keck J, Burzenski L, et al. Humanized mouse models of immunological diseases and precision medicine. Mamm Genome. 2019; 30(5-6): 123-142.

[72] Marín-Jiménez JA, Capasso A, Lewis MS, et al. Testing cancer immunotherapy in a human immune system mouse model: correlating treatment responses to human chimerism, therapeutic variables and immune cell phenotypes. Front Immunol. 2021; 12:607282.

[73] Hutson CL, Kondas AV, Ritter JM, et al. Teaching a new mouse old tricks: humanized mice as an infection model for variola virus. PLoS Pathog. 2021; 17(9):e1009633.

[74] Kutle I, Dittrich A, Wirth D. Mouse models for human herpesviruses. Pathogens. 2023; 12(7):953.

[75] Sefik E, Israelow B, Mirza H, et al. A humanized mouse model of chronic COVID-19. Nat Biotechnol. 2022; 40(6): 906-920.

[76] Dinnon KH, Leist SR, Schäfer A, et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature. 2020; 586(78): 560-566.

[77] Hansen J, Baum A, Pascal KE, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science (1979). 2020; 369(6506): 1010-1014.

[78] Kenney DJ, O’Connell AK, Turcinovic J, et al. Humanized mice reveal a macrophage-enriched gene signature defining human lung tissue protection during SARS-CoV-2 infection. Cell Rep. 2022; 39(3):110714.

[79] Dash PK, Gorantla S, Poluektova L, et al. Humanized mice for infectious and neurodegenerative disorders. Retrovirology. 2021; 18(1):13.

[80] Zhang J, Lohani SC, Cheng Y, et al. Human microglia extensively reconstitute in humanized-BLT mice with human Interleukin-34 transgene and support HIV-1 brain infection. Front Immunol. 2021; 12:672415.

[81] Mathews S, Branch Woods A, Katano I, et al. Human Interleukin-34 facilitates microglia-like cell differentiation and persistent HIV-1 infection in humanized mice. Mol Neurodegener. 2019; 14(1):12.

[82] Gillgrass A, Wessels JM, Yang JX, Kaushic C. Advances in humanized mouse models to improve understanding of HIV-1 pathogenesis and immune responses. Front Immunol. 2021; 11:617516.

[83] Brumeanu TD, Vir P, Karim AF, et al. Human-immune-system (HIS) humanized mouse model (DRAGA: HLA-A2.HLA-DR4.Rag1KO.IL-2RγcKO.NOD) for COVID-19. Hum Vaccin Immunother. 2022; 18(5):2048622.

[84] Mendoza M, Gunasekera D, Pratt KP, Qiu Q, Casares S, Brumeanu TD. The humanized DRAGA mouse (HLA-A2. HLA-DR4. RAG1 KO. IL-2R g c KO. NOD) establishes inducible and transmissible models for influenza type a infections. Hum Vaccin Immunother. 2020; 16(9): 2222-2237.

[85] Ghosh Roy S, Karim AF, Brumeanu TD, Casares SA. Reconstitution of human microglia and resident T cells in the brain of humanized DRAGA mice. Front Cell Infect Microbiol. 2024; 14:1367566.

[86] Srivastava R, Labani-Motlagh A, Chen A, et al. Development of a human glioblastoma model using humanized DRAG mice for immunotherapy. Antib Ther. 2023; 6(4): 253-264.

[87] Manocha GD, Floden AM, Puig KL, Nagamoto-Combs K, Scherzer CR, Combs CK. Defining the contribution of neuroinflammation to Parkinson’s disease in humanized immune system mice. Mol Neurodegener. 2017; 12(1):17.

[88] Hasselmann J, Coburn MA, England W, et al. Development of a chimeric model to study and manipulate human microglia in vivo. Neuron. 2019; 103(6): 1016-1033.e10.

[89] Billerbeck E, Mommersteeg MC, Shlomai A, et al. Humanized mice efficiently engrafted with fetal hepatoblasts and syngeneic immune cells develop human monocytes and NK cells. J Hepatol. 2016; 65(2): 334-343.

[90] Victor Garcia J. Humanized mice for HIV and AIDS research. Curr Opin Virol. 2016; 19: 56-64.

[91] Abdolahi S, Ghazvinian Z, Muhammadnejad S, Saleh M, Asadzadeh Aghdaei H, Baghaei K. Patient-derived xenograft (PDX) models, applications and challenges in cancer research. J Transl Med. 2022; 20(1):206.

[92] Gbyli R, Song Y, Halene S. Humanized mice as preclinical models for myeloid malignancies. Biochem Pharmacol. 2020; 174:113794.

[93] Chuprin J, Buettner H, Seedhom MO, et al. Humanized mouse models for immuno-oncology research. Nat Rev Clin Oncol. 2023; 20(3): 192-206.

[94] Zhang T, Liu W, Yang YG. B cell development and antibody responses in human immune system mice: current status and future perspective. Sci China Life Sci. 2024; 67(4): 645-652.

[95] Gade TPF, Hunt SJ, Harrison N, et al. Segmental transarterial embolization in a translational rat model of hepatocellular carcinoma. J Vasc Interv Radiol. 2015; 26(8): 1229-1237.

Rights & permissions

2026 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.